Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11848230 | 0.81 | MDM2 (0.30) | — | |
| SCHEMBL2476813 | 0.77 | PDCD1LG2 (0.40) | PDCD1LG2CD274CYP2C19 | |
| SCHEMBL2476044 | 0.76 | RAB9A (0.49) | PDCD1LG2CD274CYP2C19 | |
| SCHEMBL2476954 | 0.72 | PDCD1LG2 (0.36) | PDCD1LG2CD274CYP2C19 | |
| SCHEMBL1588343 | 0.72 | ESR1 (0.41) | PDCD1LG2CD274 | |
| SCHEMBL6714363 | 0.72 | ESR1 (0.41) | PDCD1LG2CD274 | |
| SCHEMBL1588339 | 0.72 | ESR1 (0.41) | PDCD1LG2CD274 | |
| SCHEMBL2496984 | 0.72 | BRD4 (0.43) | PDCD1LG2CD274 | |
| Hydrochloric Acid SCHEMBL2480213 | 0.72 | PDCD1LG2 (0.39) | PDCD1LG2CD274CYP2C19 | |
| SCHEMBL13712975 | 0.72 | ATR (0.37) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2159216-B1 | 3-BUTENYL-1-AMINE DERIVATIVES AND THEIR USE AS Ih MODULORS FOR THE TREATMENT OF PSYCHIATIRC DISORDERS | ORGANON NV (NL) | 2011-10-12 | — | — | EP | disclosed |
| EP-2159216-A1 | Ih - Modulators | N.V. Organon (NL) | 2010-03-03 | — | — | EP | disclosed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| EP-1035843-A2 | I h?-MODULATORS | Akzo Nobel N.V. (NL) | 2000-09-20 | — | — | EP | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| WO-1999018941-A2 | Ih-MODULATORS | AKZO NOBEL N.V. (NL) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | PDCD1LG2 3624/4885CD274 2894/4885CYP2C19 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.